Drug intelligence / Profile preview

JBZ-002

Development stage: Preclinical
Lead developer: JBZ
Modality: Small Molecules
Administration: Oral

Overview

JBZ-002 is a preclinical-stage small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) being developed by Jabez Biosciences. DHODH is a mitochondrial enzyme that catalyzes the rate-limiting step in the de novo pyrimidine synthesis pathway. By inhibiting this enzyme, JBZ-002 aims to deplete intracellular pyrimidine levels, thereby inducing metabolic stress and inhibiting the proliferation of cancer cells, particularly in small cell lung cancer (SCLC). The specific clinical development strategy for JBZ-002 is currently under evaluation.

Targets

DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)

Beyond the preview

Go deeper on JBZ-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JBZ-002.